Moderator: Tyler Gonzalez, MD, MBA
Faculty: Oliver Schipper, MD; Jonathan Kaplan, MD; Ettore Vulcano, MD; Amiethab Aiyer, MD

Description
Minimally Invasive Surgery (MIS) is an evolving field in foot and ankle surgery. Many pathologies that foot and ankle orthopaedic surgeons commonly treat can now be addressed with minimally invasive approaches. In this webinar, faculty will discuss advances in MIS foot and ankle surgery that are beyond the bunion to help guide surgeons in expanding their MIS practice. Discussion will include MIS ankle and hindfoot fusions, Zadek Osteotomy, MIS lesser toe deformity correction, and treatment of hallux rigidus with an MIS approach.

Commercial Support
2023 webinars are provided free to AOFAS members and orthopaedic residents/fellows with funding from the Orthopaedic Foot & Ankle Foundation, supported by grants from: Stryker and Arthrex, Inc.

Accreditation

The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

The AOFAS designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.

AOFAS requires all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all relevant financial relationships or affiliations during the past 12 months with any commercial interest (any entity producing, marketing, re-selling, or distributing healthcare goods and services consumed by, or used on patients). All identified conflicts of interest must be resolved and the education content vetted by AOFAS for fair balance, scientific objectivity, and appropriateness. AOFAS also requires faculty to disclose when off-label/unapproved uses of a product are discussed in a CME activity. AOFAS attests that the persons responsible for the development of this educational activity did so independently and were not influenced by commercial supporters. All financial disclosures will be provided to meeting attendees in the final program materials.

The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.

FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.

FDA Statement

Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration

As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:

Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.

Webinar Faculty Disclosures

Amiethab A. Aiyer, MD
Elsevier: Royalties – Publisher
GLW: Unpaid Consultant
Vilex: Paid Consultant

Tyler Gonzalez, MD, MBA
DJO: Paid Consultant
Exactech: Paid Consultant
Stryker: Paid Consultant
Treace Medical Concepts Inc: Paid Consultant

Jonathan Kaplan, MD
Artelon: Paid Consultant
DJO, Enovis: Paid Consultant, Royalties
Edge Surgical: Paid Consultant
Exactech Inc.: Paid Consultant
GLW Medical Innovation: Stock-privately held company
Novastep: Paid Consultant, Royalties
Surgical Fusion Technologies: Paid Consultant, Royalties
Treace Medical Concepts: Paid Consultant, Royalties

Oliver Schipper, MD
DJO, Enovis: Paid Consultant, Royalties 
Exactech: Paid Consultant, Royalties
GLW: Stock-privately held company
In2Bones: Royalties
Pressio: Stock-privately held company
Restor3d: Paid Consultant, Royalties, Stock-privately held company
Surgical Fusion Technologies: Paid Consultant, Royalties
Treace Medical: Paid Consultant, Royalties, Stock or stock options

Ettore Vulcano, MD
Vilex: Paid Consultant 
Vilex: Royalties

EDUCATION COMMITTEE DISCLOSURES (Planners)

Mike Aronow, MD
AAOS: Board Member/Committee Member
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Connecticut Orthopaedic Society: Board Member/Committee Member
CreOsso, LLC: Stock or stock options
Techniques in Foot and Ankle Surgery: Editorial/Governing board - Publications 

Jonathon D. Backus, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Marrow Access Technologies: Stock or Stock Options
Medline Unite: Paid Consultant, Royalties - Publisher

Callum Clark, MD
Arthrex Inc.: Speakers' Bureau

M. Truitt Cooper, MD
GLW: Stock-privately held company
In2Bones: Paid Consultant, Royalties
Smith & Nephew: Grant/Research Support
Stryker: Educational Grant

Canon Cornelius, MD
This individual reported nothing to disclose

Cesar de Cesar Netto, MD
AAOS: Board Member/Committee Member
AOFAS: Board Member/Committee Member
Artelon: Paid Consultant, Royalties
CurveBeam: Paid Consultant, Stock or stock options
Foot & Ankle International: Editorial/Governing board – Publications
Foot and Ankle Clinics: Editorial/Governing board - Publications
International WBCT Society: Board member/Committee Member
Medartis: Paid Consultant, Royalties
Paragon 28: Grant/Research Support, Paid Consultant, Royalties
Stryker: Paid Consultant
Tayco Brace: Stock-privately held company
Zimmer-Biomet: Paid Consultant, Royalties

Daniel C Farber, MD
JMEA: Stock-privately held company
Treace Medical Concepts, Inc.: Paid Consultant

Alena Frey
Staff
This individual reported nothing to disclose

Lauren Geaney, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
CT Othopedic Society: Board Member/Committee Member
FAI: Editorial/Governing board – Publications
Novastep: Paid Consultant
Paragon 28: Paid consultant, Royalties
Smith & Nephew: Paid consultant
Vilex: Paid consultant

Julie Glosson
Staff
This individual reported nothing to disclose

Daniel Guss, MD
AOFAS: Board Member/Committee Member
Butterfly, Inc.: Grant/Research Support
Ossio: Paid Consultant, Stock-privately held company
Paragon 28: Fellowship Support

Amgad M. Haleem Amin, MD
Vilex, LLC: Paid Consultant
Wright/Stryker medical: Paid Consultant

Tracy Harig, MD
This individual reported nothing to disclose

Jeannie Huh, MD
This individual reported nothing to disclose

Kenneth Hunt, MD
JISAKOS: Editorial/Governing board – Publications
Panther Orthopaedics: Stock-privately held company
Paragon 28: Editorial/Governing board – Publications, Paid Consultant

Kelly K. Hynes, MD
Acumed LLC: Paid Consultant
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Endo Pharmaceuticals Inc: Paid Consultant
Ortho Xcel: Paid Consultant

Brandon King, MD
Heron Therapeutics: Paid Consultant

Ashlee MacDonald, MD
This individual reported nothing to disclose

Elizabeth Martin, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

Max Michalski, MD
Arthrex Inc.: Grant/Research Support
Extremity Medical: Paid Consultant, Royalties, Speakers' Bureau

Mohamed Mokhtar Abd-Ella, MD
This individual reported nothing to disclose

Irvin Oh, MD
Innomed: Royalties

Joseph O’Neil, MD
This individual reported nothing to disclose

Christian A. Ortiz, MD
ACUMED.: Paid Consultant
AO: Board member/Committee Member

Lucas Riddle
Staff
This individual reported nothing to disclose

Charles Saltzman, MD
Lima: Unpaid Consultant
Nextremity Solutions: Paid Consultant
Paragon28, Inc.: Paid Consultant
Saunders/Mosby-Elsevier: Royalties – Publisher
Vilex, LLC: Paid Consultant
Zimmer Biomet: Royalties - Publisher

Glenn Shi, MD
This individual reported nothing to disclose

Monica Volesky, MD
Arthrex: Speakers' Bureau
Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Wright Medical: Other Financial or Material Support

Richard Zell, MD
This individual reported nothing to disclose

Jacob Rothschild Zide, MD
Orthofix: Paid consultant

All of the relevant financial relationships listed for these individuals have been mitigated.